Recovery from lipodystrophy in HIV-infected children after substitution of stavudine with zidovudine in a non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy

Pediatric Infectious Disease Journal

Volumn 31, Issue 4, 2012, Pages 384-388

  Aurpibul, Linda ^a   Puthanakit, Thanyawee ^a   Taejaroenkul, Sineenart ^a   Sirisanthana, Thira ^a   Sirisanthana, Virat ^a,b  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

children; HIV; lipodystrophy

Indexed keywords

EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; STAVUDINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THAILAND; WAIST HIP RATIO;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; MALE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STAVUDINE; THAILAND; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 84858798561     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31823f0e11     Document Type: Article

References (32)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860. (Pubitemid 28135961)
2. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528. (Pubitemid 33144917)
3. Viani RM, Araneta MR, Deville JG, et al. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2004;39:725-731. (Pubitemid 39180447)
4. Amaya RA, Kozinetz CA, McMeans A, et al. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002;21:405-410. (Pubitemid 34532934)
5. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS. 2004;18:1443-1451.
6. Beregszaszi M, Dollfus C, Levine M, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr. 2005;40:161-168. (Pubitemid 41395714)
7. Sanchez Torres AM, Munoz Muniz R, Madero R, et al. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr. 2005;164:271-276. (Pubitemid 40613041)
8. Dzwonek AB, Lawson MS, Cole TJ, et al. Body fat changes and lipodystrophy in HIV-infected children: impact of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2006;43:121-123. (Pubitemid 44306499)
9. Carr A, Samaras K, Chisholm DJ, Cooper DA. Abnormal fat distribution and use of protease inhibitors. Lancet. 1998;351:1736.
10. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2002;31:50-55.
11. Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15:2441-2444. (Pubitemid 34014613)
12. Dodds S, Blakley T, Lizzotte JM, et al. Retention, adherence, and compliance: special needs of HIV-infected adolescent girls and young women. J Adolesc Health. 2003;33:39-45. (Pubitemid 36918443)
13. Murphy DA, Sarr M, Durako SJ, et al. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157:249-255. (Pubitemid 36343379)
14. Aurpibul L, Puthanakit T, Lee B, et al. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Antivir Ther. 2007;12:1247-1254.
15. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. World Health Organization; 30 September, 2009. Available at: http://www.who.int/hiv/pub/tuapr-2009-en.pdf. Accessed August 25, 2010.
16. Vigano A, Giacomet V, Martielli L, et al. Prospective follow-up of HIV-infected children and young people with lipodystrophy [abstract 693]. In: 13th Conference on Retroviruses and Opportunistic Infections; February 14-16, 2006; Denver, CO.
17. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach: 2010 revision. 13 July, 2010. Available at: http://whqlibdoc.who.int/publications/2010/9789241599801-eng.pdf. Accessed March 28, 2011.
18. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. World Health Organization; 30 November, 2009. Available at: http://www.who.int/hiv/pub/arv/rapid-advice-art.pdf. Accessed August 25, 2010.
19. Department of Health, Ministry of Public Health. Working group on using weight and height references in evaluating the growth status of Thai children. In: Manual on Using Weight and Height References in Evaluation in Growth Status of Thai Children. Nonthaburi, Thailand: War Veterans Organization of Thailand Under Royal Patronage; 2000:28-65.
20. The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004, Clarification August 2009. Available at: http://rsc.tech-res.com. Accessed May 06, 2011.
21. Saavedra-Lozano J, Navarro M, Rojo P, et al. Status of vertically-acquired HIV-infected children at the time of their transfer to an adult clinic [abstract 692]. In: 18th Conference on Retroviruses and Opportunistic Infections; February 14 to March 2, 2011; Boston, MA.
22. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;288:207-215. (Pubitemid 34755281)
23. Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004;18:1029-1036. (Pubitemid 38591194)
24. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38:263-270. (Pubitemid 38113036)
25. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043-2050. (Pubitemid 44611057)
26. McComsey G, Bhumbra N, Ma JF, et al. First Pediatric Switch Study. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics. 2003;111:e275-e281.
27. Leung VL, Glesby MJ. Pathogenesis and treatment of HIV lipohypertrophy. Curr Opin Infect Dis. 2011;24:43-49.
28. Bartlett JG, Gallant JE. Medical Management of HIV Infection. Baltimore, MD: John Hopkins Medicine Health Publishing Business Group; 2007.
29. Aurpibul L, Puthanakit T, Sirisanthana T, et al. Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy. HIV Med. 2008;9:317-321. (Pubitemid 351517279)
30. Bunupuradah T, Puthanakit T, Boonrak P, et al. Efficacy and safety of non nucleoside reverse transcriptase inhibitor (NNRTI) based highly active antiretroviral therapy (HAART) in Thai children with HIV [abstract TUPEB128]. In: 4th International AIDS society conference; July 22-25, 2007; Sydney, Australia.
31. Kumarasamy N, Venkatesh KK, Devaleenol B, et al. Safety, tolerability and effectiveness of generic HAART in HIV-infected children in South India. J Trop Pediatr. 2009;55:155-159.
32. Zhang F, Haberer JE, Zhao Y, et al. Chinese pediatric highly active antiretroviral therapy observational cohort: a 1-year analysis of clinical, immunologic, and virologic outcomes. J Acquir Immune Defic Syndr. 2007; 46:594-598. (Pubitemid 350191053)